TARRYTOWN, N.Y., Feb. 08, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the first presentation of positive results from the Phase 3 QUASAR trial investigating EYLEA HD® (aflibercept) Injection 8 mg for the treatment of patients with macular edema following retinal vein occlusion (RVO), including those with central, branch and hemiretinal vein occlusions.…
Fri, 14 Mar 2025 11:35:32 GMT Regeneron Pharmaceuticals (NASDAQ:REGN) dropped 3% after the company's loss against Amgen (AMGN) and others in a patent case over Regeneron's blockbuster Eylea drug was affirmed by an appeal's court.
Mon, 24 Feb 2025 16:00:00 GMT Aflibercept is an inhibitor of the vascular endothelial growth factor (VEGF), which plays a key role in the abnormal formation of blood vessels in the retina, leading to vision impairment. 1) Eylea ® ...
Mon, 17 Feb 2025 22:00:00 GMT In addition to AVT06, which is a biosimilar candidate for Eylea ® (aflibercept) 2 mg, Alvotech is currently also developing AVT29, a biosimilar candidate for Eylea ® HD (aflibercept) 8 mg.
Mon, 17 Feb 2025 22:00:00 GMT In addition to AVT06, which is a biosimilar candidate for Eylea ® (aflibercept ... the Alvotech website shall be deemed part of this press release. Please visit our investor portal, and our ...
